ORAL OCTREOTIDE THERAPY IN COMBINATION WITH DIGOXIN OR LISINOPRIL
This invention relates to methods of co-administering oral octreotide and digoxin or lisinopril to a subject in need thereof.
1 . A method of treating a subject in need of oral octreotide and digoxin, the method comprising:
i) co-administering digoxin and oral octreotide to the subject;
ii) assessing the subject's clinical response to digoxin; and
iii) if the subject's clinical response to digoxin is altered when the subject is co-administered oral octreotide relative to the subject's clinical response to digoxin in the absence of octreotide, then adjusting the dose of digoxin administered to the subject.
2 . The method of claim 1 , wherein the method further comprises assessing the subject's serum level of digoxin.
3 . The method of claim 2 , wherein the subject's serum level of digoxin is decreased relative to a reference standard.
4 . The method of claim 3 , wherein the reference standard is the subject's serum level of digoxin in the absence of octreotide.
5 . The method of claim 1 , wherein the method further comprises assessing the subject's peak exposure of digoxin.
6 . The method of claim 5 , wherein the subject's digoxin peak exposure is decreased relative to a reference standard.
7 . The method of claim 6 , wherein the reference standard is the subject's digoxin peak exposure in the absence of octreotide.
8 . A method of treating a subject in need of oral octreotide and lisinopril, the method comprising:
i) co-administering oral octreotide and lisinopril to the subject;
ii) monitoring the subject's blood pressure; and
iii) if the subject's blood pressure is reduced when the subject is co-administered oral octreotide and lisinopril relative to the subject's blood pressure in the absence of octreotide, then adjusting the dose of lisinopril administered to the subject.
9 . The method of claim 8 , wherein the subject's blood pressure is reduced relative to a reference standard.
10 . The method of claim 9 , wherein the reference standard is the subject's blood pressure in the absence of octreotide.
11 . The method of claim 9 , wherein the reference standard is a blood pressure of less than 120/80.
12 . The method of claim 8 , wherein the method further comprises assessing the bioavailability of lisinopril in the subject.
13 . The method of claim 12 , wherein the bioavailability of lisinopril is increased when the subject is co-administered oral octreotide and lisinopril.
14 . (canceled)
15 . (canceled)